Payment overview · 2025
General Payments
$422.73
20 reported records · 9 companies
Healthcare provider profile · identity verified
Jennifer A Unruh, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SPARKS, NV · NPI 1992138721
Verified facts
What the public records show
CMS Open Payments records show Jennifer A Unruh, APRN received $422.73 in general payments during 2025 across 20 reported records.
PFIZER INC. accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $106.64 | 25.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $101.49 | 24.0% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $52.77 | 12.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.74 | 10.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.07 | 7.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.32 | 7.7% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $20.55 | 4.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.76 | 4.0% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $16.39 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $422.73 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $101.49 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $84.46 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $52.77 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $47.47 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $42.74 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $36.99 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.07 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.32 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.32 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $16.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 63 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
63 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 387 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 260 | 77 |
| Losartan Potassium | Losartan Potassium | 195 | 57 |
| Lisinopril | Lisinopril | 194 | 59 |
| Omeprazole | Omeprazole | 177 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 162 | 44 |
| Alprazolam | Alprazolam | 139 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 38 |
| Gabapentin | Gabapentin | 114 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 114 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 36 |
| Metformin Hcl Er | Metformin Hcl | 105 | 33 |
| Meloxicam | Meloxicam | 103 | 38 |
| Trazodone Hcl | Trazodone Hcl | 90 | 28 |
| Simvastatin | Simvastatin | 83 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 80 | 26 |
| Montelukast Sodium | Montelukast Sodium | 78 | 26 |
| Metformin Hcl | Metformin Hcl | 76 | 22 |
| Potassium Chloride | Potassium Chloride | 75 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 11 |
| Alendronate Sodium | Alendronate Sodium | 66 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 20 |
| Sertraline Hcl | Sertraline Hcl | 64 | 19 |
| Furosemide | Furosemide | 63 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 23 |
| Jardiance | Empagliflozin | 54 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 20 |
| Lorazepam | Lorazepam | 49 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 22 |
| Tramadol Hcl | Tramadol Hcl | 49 | 13 |
| Ezetimibe | Ezetimibe | 48 | 14 |
| Pregabalin | Pregabalin | 48 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 17 |
| Synthroid | Levothyroxine Sodium | 43 | 11 |
| Propranolol Hcl | Propranolol Hcl | 42 | suppressed |
| Carvedilol | Carvedilol | 41 | 14 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Prednisone | Prednisone | 39 | 25 |
| Allopurinol | Allopurinol | 37 | 11 |
| Celecoxib | Celecoxib | 36 | 15 |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | 11 |
| Eliquis | Apixaban | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Estradiol | Estradiol | 27 | 12 |
| Spironolactone | Spironolactone | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 14 |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 13 |
| Dayvigo | Lemborexant | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Prevalite | Cholestyramine | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $422.73 · 20 records | PFIZER INC. | ABRYSVO, COMIRNATY, ELIQUIS, JOURNAVX, MOUNJARO, NURTEC ODT, PREVNAR 20, REXULTI, TRELEGY ELLIPTA, VRAYLAR, Veozah, WAKIX, Wegovy, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error